2017 Version of LI-RADS for CT and MR Imaging: An Update.

The Liver Imaging Reporting and Data System (LI-RADS) is a reporting system created for the standardized interpretation of liver imaging findings in patients who are at risk for hepatocellular carcinoma (HCC). This system was developed with the cooperative and ongoing efforts of an American College of Radiology-supported committee of diagnostic radiologists with expertise in liver imaging and valuable input from hepatobiliary surgeons, hepatologists, hepatopathologists, and interventional radiologists. In this article, the 2017 version of LI-RADS for computed tomography and magnetic resonance imaging is reviewed. Specific topics include the appropriate population for application of LI-RADS; technical recommendations for image optimization, including definitions of dynamic enhancement phases; diagnostic and treatment response categories; definitions of major and ancillary imaging features; criteria for distinguishing definite HCC from a malignancy that might be non-HCC; management options following LI-RADS categorization; and reporting. ©RSNA, 2017.

[1]  M. Sherman.  Editorial: The Radiological Diagnosis of Hepatocellular Carcinoma , 2010, The American Journal of Gastroenterology.

[2]  H. Hussain,et al.  New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. , 2013, Radiology.

[3]  G. Cabibbo,et al.  Imaging appearance of treated hepatocellular carcinoma. , 2013, World Journal of Hepatology.

[4]  Sahil Mittal,et al.  Epidemiology of hepatocellular carcinoma: consider the population. , 2013, Journal of clinical gastroenterology.

[5]  M. Yu,et al.  Epidemiology of hepatocellular carcinoma. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[6]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[7]  Hepatocellular carcinoma after locoregional therapy: Magnetic resonance imaging findings in falsely negative exams. , 2016, World journal of hepatology.

[8]  L. Laurino,et al.  Relationship between cirrhosis, liver cancer, and hepatic metastases. An autopsy study , 1989, Cancer.

[9]  H. Hussain,et al.  Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver , 2010, Journal of magnetic resonance imaging : JMRI.

[10]  Erick M Remer,et al.  LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[11]  H. El‐Serag,et al.  Surveillance for hepatocellular carcinoma: in whom and how? , 2011, Therapeutic advances in gastroenterology.

[12]  H. Hussain,et al.  Hepatic arterial phase MR imaging with automated bolus-detection three-dimensional fast gradient-recalled-echo sequence: comparison with test-bolus method. , 2003, Radiology.

[13]  Ashish Kumar,et al.  Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma. , 2014, Journal of clinical and experimental hepatology.

[14]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[15]  Comparison of MRI pulse sequences for prediction of size of hepatocellular carcinoma at explant evaluation. , 2014, AJR. American journal of roentgenology.

[16]  H. Chalian,et al.  Threshold for Enhancement in Treated Hepatocellular Carcinoma on MDCT: Effect on Necrosis Quantification. , 2016, AJR. American journal of roentgenology.

[17]  Carlos Cuevas,et al.  Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma , 2015, Annals of Internal Medicine.

[18]  Roberto Passariello,et al.  Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. , 2003, Radiology.

[19]  Claude B. Sirlin,et al.  LI‐RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI‐RADS Management Working Group and future directions , 2015, Hepatology.

[20]  H. Hussain,et al.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially‐enhancing liver mass , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  J. Willatt,et al.  MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. , 2008, Radiology.

[22]  V. Vilgrain,et al.  Hepatic nodules in Budd-Chiari syndrome: imaging features. , 1999, Radiology.

[23]  Onofrio A Catalano,et al.  Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

[24]  A. Ragozzino,et al.  Transient hepatic intensity differences: part 2, Those not associated with focal lesions. , 2007, AJR. American journal of roentgenology.

[25]  Puneet S. Sharma,et al.  Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real‐time imaging , 2011, Journal of magnetic resonance imaging : JMRI.

[26]  S. Fan,et al.  Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases , 1992, Cancer.

[27]  C. Zettler,et al.  Prevalence study of metastases in cirrhotic livers. , 2003, Hepato-gastroenterology.

[28]  C. Sirlin,et al.  Imaging-based diagnostic systems for hepatocellular carcinoma. , 2013, AJR. American journal of roentgenology.

[29]  P. Hytiroglou,et al.  The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation , 2002, European Radiology.

[30]  F. Sardanelli,et al.  Regenerative nodules in patients with chronic Budd-Chiari syndrome: a longitudinal study using multiphase contrast-enhanced multidetector CT. , 2010, European journal of radiology.

[31]  M. Kumar,et al.  Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update , 2016, Hepatology International.

[32]  C. Ayuso,et al.  Imaging of HCC , 2012, Abdominal Imaging.

[33]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[34]  Tae Hyun Kim,et al.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma , 2015, Korean journal of radiology.

[35]  O. Matsui,et al.  Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. , 1992, Radiology.

[36]  B. Saar,et al.  Radiological diagnosis of hepatocellular carcinoma , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[37]  Aya Kamaya,et al.  Quantitatively defining washout in hepatocellular carcinoma. , 2013, AJR. American journal of roentgenology.

[38]  Tara L. Kieffer,et al.  Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .

[39]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[40]  G. Andreisek,et al.  CT and MR imaging of hepatocellular carcinoma. , 2011, Journal of gastrointestinal and liver diseases : JGLD.

[41]  D. Kleiner,et al.  Nodular regenerative hyperplasia: Not all nodules are created equal , 2006, Hepatology.

[42]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[43]  石神 康生.  Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images : correlation with histopathologic findings , 2011 .